CBI2026 Nucleic Acid Therapeutics Innovation Conference Announces Agenda and Speaker Lineup
Haichang Biotech
Innovative Formulation Developer
mRNA technology has garnered significant industry attention due to its outstanding application outcomes, and nucleic acid therapeutics have evolved from a frontier research direction into a key track for global new drug development. As the industry enters a phase of in-depth development, numerous challenges have emerged:
How can mRNA drugs expand their application scenarios and establish a presence in therapeutic areas such as oncology and autoimmune diseases? How can small nucleic acid therapies break through the market limitations of rare diseases and enter the vast blue ocean of mainstream indications, including oncology, central nervous system disorders, and chronic diseases? How can we achieve true large-scale breakthroughs in delivery systems and manufacturing processes to overcome critical bottlenecks?
September 4–5, 2026[CBI2026 Biopharmaceutical Innovation Expo – Nucleic Acid Drug Innovation Development Conference]To be held at the Suzhou International Expo Center. Co-hosted by Weichun Technology and YaoRongQuan, this conference focuses on two core themes: mRNA drugs and vaccines, and small nucleic acid drug development. It brings together seasoned industry professionals with the aim of breaking down barriers across the entire chain of technological R&D, clinical development, and process manufacturing, thereby elucidating the path from technical validation to large-scale commercialization for nucleic acid therapeutics. Registration is open—join us for on-site exchanges!
Forum Name:CBI 2026 Nucleic Acid Drug Innovation Development Conference
Forum Schedule:September 4–5, 2026
Forum Location:Hall B, Booth B104, Suzhou International Expo Center
Co-Hosted by:Weichun Technology, Yaorong Circle
*Sorted alphabetically by first letter of name (A–Z); no special significance intended
Professor Song Xiangrong, Ph.D. in Pharmaceutics, Postdoctoral Fellow in Biology, Visiting Scholar in Nanomedicine and Immunology at Harvard Medical School, is currently a Principal Investigator/Doctoral Supervisor at the State Key Laboratory of Biotherapy, Sichuan University. He has been selected as a National-Level Young Talent, serves as the Chief Scientist for the National Key R&D Program, and is the General Manager/Scientific Founder of Weijin Biotech.
With nearly 20 years of experience in the research and development of innovative drugs based on targeted delivery, I have published over 70 first-author or corresponding-author SCI papers in prestigious journals such as Nat Nanotechnol, Nat Comm, and Sci Adv. I have filed 107 invention patents (including 29 international patents). The nano-adjuvant (WGa01), which I spearheaded, has received Emergency Use Authorization (EUA) for market launch in China. I have led the development of Class 1 mRNA nanomedicines, securing one approval for Phase II clinical trials, four approvals for Phase I clinical trials, and advancing three candidates into clinical trials. Additionally, I obtained two clinical trial approvals for small-molecule targeted drugs in China. I was awarded the Grand Prize (highest honor) in the 2022 National Disruptive Technology Innovation Competition organized by the Ministry of Science and Technology of China. I currently serve as an Editorial Board Member for Signal Transduction and Targeted Therapy, Asian Journal of Pharmaceutical Sciences, and European Journal of Pharmaceutical Sciences; a Committee Member of the Nucleic Acid Drug Branch of the Chinese Pharmaceutical Association; a Youth Committee Member of the Pharmaceutics Professional Committee of the Chinese Pharmaceutical Association; a Committee Member of the Nano-Biotechnology Branch of the China Medical Biotechnology Association; and the Chairman of the SAPA Western Innovation Center of the Chinese-American Pharmacists Association.
Ph.D. from Zhejiang University, responsible for the preclinical development of Haichang Biotech’s nucleic acid innovative drug pipeline. Published 8 SCI-indexed papers and filed over ten invention patents. The HC016 project, led in its development, has entered Phase I clinical trials, with multiple projects in the IND-enabling stage. Research interests include the application of siRNA, ASO, microRNA, and other drugs in metabolic diseases, oncology, and CNS disorders. Possesses in-depth expertise in sequence design, chemical modifications, and delivery systems for oligonucleotide therapeutics.
• 30 years of in-depth expertise in virology, with extensive experience in fundamental virology research as well as the development and production of viral vaccines and therapeutics
• A recognized scholar in the field of virology, with over 310 publications on virology and drug development in internationally renowned journals, and more than 70 granted patents
• Principal investigator for the National 973 Program, the “11th Five-Year” and “12th Five-Year” Major Projects for New Drug Innovation, the “13th Five-Year” Major Science and Technology Project on Infectious Disease Control, the National Key R&D Program of China, as well as drug development projects funded by the Canadian AIDS Research Foundation and the Canadian Institutes of Health Research.
• Led early-stage research on over ten mRNA-based therapeutics, including prophylactic vaccines against COVID-19, influenza, and RSV, as well as therapeutic HPV vaccines; conducted R&D on multiple viral vaccines and antiviral agents, such as the anti-HIV drug IMB26 and the EV71 vaccine; obtained two FDA approvals.
• Professor and Researcher, Institute of Medicinal Biotechnology, Peking Union Medical College
Shuqing Chen, Ph.D., is a Professor and Doctoral Supervisor at the College of Pharmaceutical Sciences, Zhejiang University. He serves as a Standing Committee Member of the Pharmacogenomics Professional Committee of the Chinese Pharmacological Society and as the Honorary Chairman of the Biochemical Pharmaceuticals Professional Committee of the Zhejiang Pharmaceutical Association. He has published 240 papers in prestigious domestic and international journals, including Cell, Nature Communications, Advanced Materials, and Biomaterials, and has served as editor-in-chief or co-editor for 16 books and textbooks. He has presided over five projects funded by the National Natural Science Foundation of China (including two Key Projects), two sub-projects under the National Major Special Project for New Drug Innovation, and one key project under the National Key R&D Program’s “Precision Medicine Research” special initiative. He has completed five major scientific research achievements, receiving the Third Prize of Zhejiang Provincial Science and Technology Progress Award twice, the Second Prize of Zhejiang Provincial Science and Technology Progress Award once, the Second Prize of Zhejiang Provincial Natural Science Award once, and the Third Prize of Zhejiang Provincial Natural Science Award once. He was selected as a Leading Talent in Scientific and Technological Innovation in Zhejiang Province. The personalized tumor vaccine he designed from scratch has received clinical trial approval from both the Center for Drug Evaluation (CDE) in China and the U.S. Food and Drug Administration (FDA), and clinical trials are currently underway.
Dr. Du Zhiqiang (Danny) serves as the Chief Operating Officer (COO) of the company, with overall responsibility for the pipeline development of innovative oligonucleotide therapeutics, optimizing and accelerating the industrialization of the pipeline, and promoting and expanding the company’s international collaborations and comprehensive influence.
Seven-Year Integrated Undergraduate and Master’s Program in Clinical Medicine, China Medical University
Attending Physician, Shengjing Hospital of China Medical University
Ph.D. in Biology, Texas Tech University
Postdoctoral Fellow in Tumor Biology at The University of Texas MD Anderson Cancer Center
Core R&D Role at a Renowned MNC Pharmaceutical Company
Vice President of R&D at a Major Domestic Listed Pharmaceutical Company
Dr. Du Zhiqiang has nearly 20 years of experience in drug R&D and industrialization operations, having served in core R&D roles at renowned multinational pharmaceutical companies such as Novartis, Johnson & Johnson, and Amgen. In recent years, he has served as Deputy General Manager, overseeing R&D, at major domestically listed companies Shanghai Renhui Biopharmaceutical Co., Ltd. and Tonghua Dongbao Pharmaceutical Co., Ltd. Dr. Du possesses extensive expertise in pharmaceutical R&D, regulatory submissions, clinical medicine, industrial development, and corporate operational management, with profound understanding and accomplishments particularly in the field of chronic diseases.
Dr. Du Zhiqiang has joined Xuanjing Biologics as Chief Operating Officer (COO). He will be primarily responsible for: the initiation of R&D projects for the company’s innovative pipeline and its forward-looking, strategic layout; leading the R&D Center in preclinical research, regulatory submissions, clinical development, and the liaison and maintenance of related resources for pipelines under investigation; and promoting and expanding key initiatives related to the company’s international operations, collaborations, and development.
Dr. Hu Rongkuan, Founder and Chief Executive Officer of Xingrui Medicine, is a Senior Engineer (Professor-level) and an Industry Professor at the School of Biomedical Engineering of the University of Science and Technology of China and the School of Pharmaceutical Sciences of Soochow University. With extensive experience in the research and development of nucleic acid therapeutics and mRNA vaccines, he has led the development of multiple RNA-based drugs into clinical and commercialization stages, and has filed patents and published over 60 SCI-indexed papers. Dr. Hu has been honored with titles such as Jiangsu Province’s “Dual Innovation Talent,” Suzhou City’s “Gusu Leading Talent for Innovation and Entrepreneurship,” and Suzhou Industrial Park’s “Science and Technology Leading Talent.” He earned his Ph.D. from the University of Science and Technology of China, holds an EMBA from CEIBS (China Europe International Business School), and conducted postdoctoral research at the University of Texas Southwestern Medical Center.
Former Executive President of Fosun Pharma, Global Head of R&D and Chief Medical Officer, Chair of the Scientific Committee, and Fosun Global Partner. In early 2020, he spearheaded the collaboration between Fosun Pharma and Germany’s BioNTech, contributing to the development of the world’s first mRNA COVID-19 vaccine. He directly led the R&D and market launch of this vaccine (Comirnaty) in Greater China, including Hong Kong, Macao, and Taiwan, thereby driving the development of China’s mRNA industry. He previously provided direct leadership for the global R&D and commercialization of multiple blockbuster small-molecule and biologic anticancer drugs, including Ixazomib and Isatuximab, and oversaw the R&D and launch in China of several innovative drugs such as Isafoximib and Avatrombopag. In 2013, he pioneered a clinical registration model for extending global Phase III trials to China, paving the way for the direct registration and market approval of innovative drugs in China using global Phase III clinical data. He has received more than 20 awards, including the Fourth Translational Medicine International Cooperation Award and the International Young Scientist Award for Gastrointestinal Cancer. He has published over 100 papers (including in The New England Journal of Medicine, The Lancet, and Nature Medicine) and authored or edited eight monographs in Chinese, English, and Japanese. He formerly served as Global Vice President at Sanofi, Director of the Shanghai Key Laboratory for Stem Cell Therapy, and Deputy Director of the Oncology Committee of the China Pharmaceutical Innovation Promotion Association.
Formerly a graduate supervisor at the Beijing Institute of Genomics, Chinese Academy of Sciences; Principal Investigator for the Ministry of Science and Technology’s “Innovation 2020” vaccine project; Chief Scientist for the National 13th Five-Year Plan Major Special Project on Infectious Diseases. Participated in the 11th Five-Year Plan Major Special Project for New Drug Research and Development; led key projects under the “Major New Drug Creation” initiative during the 12th and 13th Five-Year Plan periods. Currently overseeing multiple research grants funded by the Ministry of Science and Technology and local science and technology commissions. Serves as a review expert for the National Natural Science Foundation of China as well as the natural science foundations of Zhejiang, Fujian, and other provinces; serves on the editorial boards of several journals; has published more than 60 SCI-indexed papers. The Qichensheng team has over ten years of experience in investigator-initiated exploratory clinical studies in the field of cancer vaccines.
Ph.D. from the State Key Laboratory of Bio-organic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences; Visiting Scholar at the National Institutes of Health (NIH), USA; former Associate Researcher at The Scripps Research Institute (TSRI), USA. Shanghai Industrial Elite Leading Talent; Shanghai Dongfang Talent.
With over 20 years of experience in corporate drug R&D, Dr. Ma has conducted in-depth research in the fields of carbohydrate chemistry and biology. He has accumulated extensive knowledge and expertise in the isolation, extraction, and chemical synthesis of saponins, the active ingredients of traditional Chinese medicines. He has many years of research experience and accumulation in the synthesis and biological activity of cutting-edge polysaccharide macromolecule conjugates, such as glycolipids, glycopeptides, and glycoproteins. In particular, he has made pioneering contributions to the crystallization and high-resolution structural analysis of transmembrane proteins mediated by glycolipids. He has also carried out research on the synthesis and biological activity of polyphenols, including tea polyphenols, as well as more complex oligomers. Dr. Ma has led teams for many years in the design and development of antibody-drug conjugate (ADC) therapeutics and established a PROTAC R&D platform. He has maintained long-term collaborations with multiple European and American companies on novel drug research and was deeply involved in the R&D of XPOVIOTM (selinexor), a marketed XPO1 antagonist.
Dr. Ma Xingquan has studied and worked at prestigious academic research institutions in China and the United States. He has published more than 20 academic papers and innovative patents in core journals both domestically and internationally, including JACS, Angewandte Chemie (ANGEW), Langmuir, Organic & Biomolecular Chemistry (OBC), and Journal of Materials Chemistry Letters (JMCL).
Joined Medicilon Biopharma in 2018, established the Nanhui R&D Center team with a scale of over 1,000 members, and spearheaded the creation of Medicilon’s drug development platforms for PROTACs, ADCs, and small nucleic acids, demonstrating profound expertise and insights in multiple cutting-edge areas of pharmaceutical research and development.
Dr. Tian Weiwei currently serves as Vice President of R&D at Sinomab Group and General Manager of Sinomab Therapeutics (Suzhou). His research primarily focuses on the creation of novel small interfering nucleic acid drugs and the development of delivery technologies. He earned his Ph.D. in Organic Chemistry from the University of Delaware in the United States and conducted pharmaceutical-related research at The Scripps Research Institute (TSRI) in the U.S. and the Agency for Science, Technology and Research (A*STAR) in Singapore.
Mr. Zhuocheng Tu has over nine years of experience in investment banking and private equity investment. He previously worked at Fengchuan Capital, where he led and participated in investments in life and healthcare projects. Prior to joining Fengchuan Capital, Mr. Tu served in the Investment Banking Departments of China International Capital Corporation (CICC) and Haitong International, participating in various projects including initial public offerings (IPOs) and mergers and acquisitions (M&A) for multiple companies listed on the A-share, Hong Kong, and U.S. stock markets. Mr. Tu holds a Bachelor’s degree in Economics from Shanghai University of Finance and Economics.
Dr. Li Wang, Ph.D. in Immunology, graduated from the Academy of Military Medical Sciences. She currently serves as Deputy General Manager of Xuanzhu Biotechnology Co., Ltd., overseeing business units including small nucleic acid development, clinical development, and business development. With over 15 years of experience in new drug development and related fields, she possesses comprehensive expertise in managing the entire drug development lifecycle, from early-stage research and project initiation to commercialization. Long committed to the research and development of novel therapeutics for major diseases such as cancer and metabolic disorders, she has played a pivotal role in advancing the company’s innovative drug pipeline, clinical development, and business expansion. Dr. Wang has led the R&D efforts for multiple innovative drugs at Xuanzhu Biotech, facilitating the market approval of three innovative drugs across multiple indications and securing overseas licensing deals. She brings extensive experience in project initiation, formulation of differentiated development strategies, execution of preclinical and clinical development, and out-licensing/collaborative partnerships.
He Wenjun, General Manager of the Chromatography Division at Weichun Biotechnology (Guangzhou) Co., Ltd., is a seasoned professional in the scientific instrumentation industry.
Holds a Master’s degree in Medicinal Chemistry from the Chinese Academy of Sciences and possesses nearly a decade of experience in scientific instrument market development. With years of deep expertise in the chromatography industry, combines solid technical proficiency with exceptional business acumen.
Excels in technology-driven sales, with the ability to accurately identify customer pain points in chromatographic analysis and provide tailored solutions; possesses team management experience and is adept at leading teams to exceed high-performance targets. Committed to advancing the market adoption of domestically produced scientific instruments and consumables through professional product expertise and efficient market strategies.
— Master’s degree from Peking University Health Science Center; MBA from Harvard University.
— Formerly served as Deputy Director of the Beijing Product Design Center of Taiji Group, and Secretary of the Board of Directors of the Taiji Anti-Cancer Science Foundation,
— Joined 3D Medicines in 2016, successively serving as Head of Regulatory Affairs and Deputy General Manager.
— Member of the Hong Kong Investor Relations Association; Member of the 4th Pharmaceutical Innovation Investment Professional Committee of the China Pharmaceutical Innovation and Promotion Association (PhIRDA).
Dr. Xiong Changyun holds a Ph.D. from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and completed his postdoctoral fellowship at the National Cancer Institute (NCI), National Institutes of Health (NIH), USA. He has previously held positions at renowned pharmaceutical companies including BD, Novartis, Amgen, and Aim Vaccine. Currently, he is the Founder and CEO of Ningbo Junjian Biotech. With over two decades of deep expertise in the biopharmaceutical industry, Dr. Xiong has led the research, development, and industrialization of multiple COVID-19 vaccines and antibody drugs, with a particular focus on self-amplifying mRNA technology. He has published more than 20 academic papers and holds over 20 invention patents, specializing in end-to-end biologic drug development, process scale-up, and commercial implementation.
B.S. in Pharmacy, West China University of Medical Sciences (1992); M.S. in Neuropsychopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (1995); Ph.D. in Neuropsychopharmacology, Baylor College of Medicine, USA (2000); Postdoctoral Fellow, Department of Neurobiology, Duke University, USA (2000–2003). Currently Senior Investigator at the Center for Excellence in Brain Science and Intelligence Technology/Institute of Neuroscience, Chinese Academy of Sciences, and Shanghai Research Center for Brain Science and Brain-Inspired Intelligence; Distinguished Professor at the University of Chinese Academy of Sciences, ShanghaiTech University, and Shanghai Jiao Tong University. Standing Director of the Chinese Society for Neuroscience; Vice Chair of the Basic and Clinical Neurology Branch and Vice Chair of the Basic and Clinical Psychiatry Branch of the Chinese Society for Neuroscience; Standing Committee Member of the Pharmacotherapy Committee of the China Association Against Epilepsy. Research interests include elucidating mechanisms of neurological disorders and developing innovative therapeutics, as well as establishing non-human primate models of brain diseases, objective biomarkers, and evaluation paradigms. Authored over 100 peer-reviewed publications and holds more than 20 granted patents.
Ph.D. in Medical Genetics from Uppsala University, Sweden; Postdoctoral Fellow in Cancer Genetics and Neurogenetics at the University of California, San Francisco/Los Angeles; Former Research Fellow in the Division of Rheumatology, Department of Medicine, School of Medicine, University of California, San Diego. Upon returning to China, appointed as Qianjiang Scholar Distinguished Professor and Researcher at Shenzhen Research Institute of Sun Yat-sen University. Currently serves as Industry Professor at the Center for Cell and Gene Therapy Research, Southern University of Science and Technology. Founder of Ruimeaona (Guangzhou) Biopharmaceutical Technology Co., Ltd., with long-term dedication to the research and development of cancer genomics, cancer mRNA vaccines, and large RNA models.
Dr. Xudong Yuan is the Founder and CEO of ACON Pharma. He earned his Ph.D. in Pharmaceutics from the College of Pharmacy at the University of Georgia in the United States. After graduation, he served as a researcher at Nova Southeastern University and the Long Island University College of Pharmacy, where he conducted extensive pharmaceutical research, with a particular focus on nucleic acid drug delivery systems. Dr. Yuan later transitioned from academia to the pharmaceutical industry, holding various roles as a pharmaceutical scientist at Johnson & Johnson, RB (Reckitt Benckiser), and GlaxoSmithKline. In these positions, he contributed to the research and product development of diverse drug formulations and modified-release technologies. He also served as Director of Research and Vice President at pharmaceutical companies in New Jersey and Philadelphia, where he was primarily responsible for the development of complex formulations, including liposomal, nanoparticle, nanocrystal, and microsphere-based injectables, as well as ophthalmic solutions and nasal sprays. In these roles, he oversaw the entire lifecycle of drug product development, manufacturing, and regulatory submissions. In 2020, Dr. Yuan founded ACON Pharma, which specializes in the research and development of siRNA and mRNA nucleic acid therapeutics, along with advanced drug delivery systems.
Dr. Zhao, who holds a Ph.D. from the Institute of Neuroscience, Chinese Academy of Sciences, brings over a decade of R&D experience in biopharmaceuticals, with extensive expertise in oligonucleotide therapeutics, gene editing, and xenotransplantation research. Currently, Dr. Zhao is responsible for formulating strategic plans, leading project initiation and key technology development, expanding scientific collaborations, building interdisciplinary teams, safeguarding intellectual property rights, and promoting public understanding of nucleic acid-based drugs to drive innovation and advancement in the field.
With over 20 years of extensive expertise in the field of chromatography, Weichun Technology masters leading high-pressure chromatography media technologies. Its comprehensive product portfolio covers the entire workflow from analytical to industrial-scale preparation, providing global pharmaceutical companies with analytical testing and purification solutions spanning R&D, clinical development, and industrial manufacturing.
The company achieves fully independent, end-to-end production from microspheres to finished products, ensuring consistent product quality and reliable supply. Company MicroPulite®Series Analytical Columns and PrePulite®The performance of our preparative chromatography media series rivals that of leading international brands, with products exported to over 20 countries and regions worldwide. Leveraging an annual production capacity of 25 tons of silica-based chromatography media, we ensure stable supply and rapid delivery. Our comprehensive product portfolio precisely meets the critical needs of the pharmaceutical industry from R&D to large-scale production, facilitating seamless process transfer and scale-up for our customers.
Weichun Technology is committed to supporting global pharmaceutical R&D and manufacturing with cost-effective products, a reliable supply chain, and efficient services, benefiting hundreds of millions of users.
Registration:
ConferenceLimited-Time Free Access(Subject to capacity limits; registration is on a first-come, first-served basis. This is a pre-registration; successful enrollment is confirmed upon approval of the application.) Accommodation and meals are at the participant's own expense.
